Top

Published in:

01-03-2018 | Invited Review

The SAFE pathway for cardioprotection: is this a promising target?

Authors: Nkanyiso Hadebe, Martin Cour, Sandrine Lecour

Published in: Basic Research in Cardiology | Issue 2/2018

Abstract

The survivor activating factor enhancement (SAFE) pathway was discovered as an alternative intrinsic pro-survival signaling pathway to the reperfusion injury salvage kinase pathway for cardioprotection against ischemia–reperfusion injury. The delineation of this pathway, made of key components such as cytokines of the immune system and transcription factors, has brought major advancements in our understanding on how the heart is able to protect itself against ischemia–reperfusion injury. In this viewpoint, we describe the major steps leading to the discovery of the SAFE pathway in small animal models to date and we discuss its translation to large animals and humans.

Balakumar P, Singh M (2006) Anti-tumour necrosis factor-alpha therapy in heart failure: future directions. Basic Clin Pharmacol Toxicol 99:391–397. https://doi.org/10.1111/j.1742-7843.2006.pto_508.x CrossRefPubMed

Boengler K, Buechert A, Heinen Y, Roeskes C, Hilfiker-Kleiner D, Heusch G, Schulz R (2008) Cardioprotection by ischemic postconditioning is lost in aged and STAT3-deficient mice. Circ Res 102:131–135. https://doi.org/10.1161/CIRCRESAHA.107.164699 CrossRefPubMed

Boengler K, Hilfiker-Kleiner D, Drexler H, Heusch G, Schulz R (2008) The myocardial JAK/STAT pathway: from protection to failure. Pharmacol Ther 120:172–185. https://doi.org/10.1016/j.pharmthera.2008.08.002 CrossRefPubMed

Boengler K, Hilfiker-Kleiner D, Heusch G, Schulz R (2010) Inhibition of permeability transition pore opening by mitochondrial STAT3 and its role in myocardial ischemia/reperfusion. Basic Res Cardiol 105:771–785. https://doi.org/10.1007/s00395-010-0124-1 CrossRefPubMedPubMedCentral

Boengler K, Ungefug E, Heusch G, Schulz R (2013) The STAT3 inhibitor static impairs cardiomyocyte mitochondrial function through increased reactive oxygen species formation. Curr Pharm Des 19:6890–6895. https://doi.org/10.2174/138161281939131127115940 CrossRefPubMed

Brulhart-Meynet MC, Braunersreuther V, Brinck J, Montecucco F, Prost JC, Thomas A, Galan K, Pelli G, Pedretti S, Vuilleumier N, Mach F, Lecour S, James RW, Frias MA (2015) Improving reconstituted HDL composition for efficient post-ischemic reduction of ischemia reperfusion injury. PLoS ONE 10:e0119664. https://doi.org/10.1371/journal.pone.0119664 CrossRefPubMedPubMedCentral

Deuchar GA, Opie LH, Lecour S (2007) TNFalpha is required to confer protection in an in vivo model of classical ischaemic preconditioning. Life Sci 80:1686–1691. https://doi.org/10.1016/j.lfs.2007.01.040 CrossRefPubMed

Downey JM, Cohen MV (1997) Signal transduction in ischemic preconditioning. Adv Exp Med Biol 430:39–55. https://doi.org/10.1007/978-1-4615-5959-7_4 CrossRefPubMed

Downey JM, Davis AM, Cohen MV (2007) Signaling pathways in ischemic preconditioning. Heart Fail Rev 12:181–188. https://doi.org/10.1007/s10741-007-9025-2 CrossRefPubMed

10.

Frias MA, Lecour S, James RW, Pedretti S (2012) High density lipoprotein/sphingosine-1-phosphate-induced cardioprotection: role of STAT3 as part of the SAFE pathway. JAKSTAT 1:92–100. https://doi.org/10.4161/jkst.19754 PubMedPubMedCentral

11.

Frias MA, Pedretti S, Hacking D, Somers S, Lacerda L, Opie LH, James RW, Lecour S (2013) HDL protects against ischemia reperfusion injury by preserving mitochondrial integrity. Atherosclerosis 228:110–116. https://doi.org/10.1016/j.atherosclerosis.2013.02.003 CrossRefPubMed

12.

Gedik N, Kottenberg E, Thielmann M, Frey UH, Jakob H, Peters J, Heusch G, Kleinbongard P (2017) Potential humoral mediators of remote ischemic preconditioning in patients undergoing surgical coronary revascularization. Sci Rep 7:12660. https://doi.org/10.1038/s41598-017-12833-2 CrossRefPubMedPubMedCentral

13.

Gent S, Skyschally A, Kleinbongard P, Heusch G (2017) lschemic preconditioning in pigs: a causal role for signal transducer and activator of transcription 3. Am J Physiol Heart Circ Physiol 312:H478–H484. https://doi.org/10.1152/ajpheart.00749.2016 CrossRefPubMed

14.

Gough DJ, Koetz L, Levy DE (2013) The MEK–ERK pathway is necessary for serine phosphorylation of mitochondrial STAT3 and Ras-mediated transformation. PLoS ONE 8:e83395. https://doi.org/10.1371/journal.pone.0083395 CrossRefPubMedPubMedCentral

15.

Hamid T, Gu Y, Ortines RV, Bhattacharya C, Wang G, Xuan YT, Prabhu SD (2009) Divergent tumor necrosis factor receptor-related remodeling responses in heart failure: role of nuclear factor-kappaB and inflammatory activation. Circulation 119:1386–1397. https://doi.org/10.1161/CIRCULATIONAHA.108.802918 CrossRefPubMedPubMedCentral

16.

Hausenloy DJ, Barrabes JA, Botker HE, Davidson SM, Di Lisa F, Downey J, Engstrom T, Ferdinandy P, Carbrera-Fuentes HA, Heusch G, Ibanez B, Iliodromitis EK, Inserte J, Jennings R, Kalia N, Kharbanda R, Lecour S, Marber M, Miura T, Ovize M, Perez-Pinzon MA, Piper HM, Przyklenk K, Schmidt MR, Redington A, Ruiz-Meana M, Vilahur G, Vinten-Johansen J, Yellon DM, Garcia-Dorado D (2016) Ischaemic conditioning and targeting reperfusion injury: a 30 year voyage of discovery. Basic Res Cardiol 111:70. https://doi.org/10.1007/s00395-016-0588-8 CrossRefPubMedPubMedCentral

17.

Hausenloy DJ, Duchen MR, Yellon DM (2003) Inhibiting mitochondrial permeability transition pore opening at reperfusion protects against ischaemia–reperfusion injury. Cardiovasc Res 60:617–625. https://doi.org/10.1016/j.cardiores.2003.09.025 CrossRefPubMed

18.

Hausenloy DJ, Lecour S, Yellon DM (2011) Reperfusion injury salvage kinase and survivor activating factor enhancement prosurvival signaling pathways in ischemic postconditioning: two sides of the same coin. Antioxid Redox Signal 14:893–907. https://doi.org/10.1089/ars.2010.3360 CrossRefPubMed

19.

Heusch G, Musiolik J, Gedik N, Skyschally A (2011) Mitochondrial STAT3 activation and cardioprotection by ischemic postconditioning in pigs with regional myocardial ischemia/reperfusion. Circ Res 109:1302–1308. https://doi.org/10.1161/CIRCRESAHA.111.255604 CrossRefPubMed

20.

Heusch G, Musiolik J, Kottenberg E, Peters J, Jakob H, Thielmann M (2012) STAT5 activation and cardioprotection by remote ischemic preconditioning in humans: short communication. Circ Res 110:111–115. https://doi.org/10.1161/CIRCRESAHA.111.259556 CrossRefPubMed

21.

Hilfiker-Kleiner D, Kaminski K, Podewski E, Bonda T, Schaefer A, Sliwa K, Forster O, Quint A, Landmesser U, Doerries C, Luchtefeld M, Poli V, Schneider MD, Balligand JL, Desjardins F, Ansari A, Struman I, Nguyen NQ, Zschemisch NH, Klein G, Heusch G, Schulz R, Hilfiker A, Drexler H (2007) A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell 128:589–600. https://doi.org/10.1016/j.cell.2006.12.036 CrossRefPubMed

22.

Hilfiker-Kleiner D, Shukla P, Klein G, Schaefer A, Stapel B, Hoch M, Muller W, Scherr M, Theilmeier G, Ernst M, Hilfiker A, Drexler H (2010) Continuous glycoprotein-130-mediated signal transducer and activator of transcription-3 activation promotes inflammation, left ventricular rupture, and adverse outcome in subacute myocardial infarction. Circulation 122:145–155. https://doi.org/10.1161/CIRCULATIONAHA.109.933127 CrossRefPubMed

23.

Hu H, Nan J, Sun Y, Zhu D, Xiao C, Wang Y, Zhu L, Wu Y, Zhao J, Wu R, Chen J, Yu H, Hu X, Zhu W, Wang J (2017) Electron leak from NDUFA13 within mitochondrial complex I attenuates ischemia–reperfusion injury via dimerized STAT3. Proc Natl Acad Sci USA. https://doi.org/10.1073/pnas.1704723114

24.

Kalakech H, Hibert P, Prunier-Mirebeau D, Tamareille S, Letournel F, Macchi L, Pinet F, Furber A, Prunier F (2014) RISK and SAFE signaling pathway involvement in apolipoprotein A–I-induced cardioprotection. PLoS ONE 9:e107950. https://doi.org/10.1371/journal.pone.0107950 CrossRefPubMedPubMedCentral

25.

Karliner JS (2013) Sphingosine kinase and sphingosine 1-phosphate in the heart: a decade of progress. Biochim Biophys Acta 1831:203–212. https://doi.org/10.1016/j.bbalip.2012.06.006 CrossRefPubMed

26.

Kelly RF, Lamont KT, Somers S, Hacking D, Lacerda L, Thomas P, Opie LH, Lecour S (2010) Ethanolamine is a novel STAT-3 dependent cardioprotective agent. Basic Res Cardiol 105:763–770. https://doi.org/10.1007/s00395-010-0125-0 CrossRefPubMed

27.

Kleinbongard P, Skyschally A, Gent S, Pesch M, Heusch G (2018) STAT3 as a common signal of ischemic conditioning: a lesson on “rigor and reproducibility” in preclinical studies on cardioprotection. Basic Res Cardiol 113:3. https://doi.org/10.1007/s00395-017-0660-z CrossRef

28.

Kottenberg E, Musiolik J, Thielmann M, Jakob H, Peters J, Heusch G (2014) Interference of propofol with signal transducer and activator of transcription 5 activation and cardioprotection by remote ischemic preconditioning during coronary artery bypass grafting. J Thorac Cardiovasc Surg 147:376–382. https://doi.org/10.1016/j.jtcvs.2013.01.005 CrossRefPubMed

29.

Kwan JC, Gao L, Macdonald PS, Hicks M (2015) Cardio-protective signalling by glyceryl trinitrate and cariporide in a model of donor heart preservation. Heart Lung Circ 24:306–318. https://doi.org/10.1016/j.hlc.2014.10.001 CrossRefPubMed

30.

Lacerda L, Jacobs M, Opie L, Lecour S (2011) Ischaemic postconditioning confers protection via TNF: identifying the cellular origin of TNF. Eur Heart J 32:662. https://doi.org/10.1093/eurheartj/ehr324

31.

Lacerda L, McCarthy J, Mungly SF, Lynn EG, Sack MN, Opie LH, Lecour S (2010) TNFalpha protects cardiac mitochondria independently of its cell surface receptors. Basic Res Cardiol 105:751–762. https://doi.org/10.1007/s00395-010-0113-4 CrossRefPubMedPubMedCentral

32.

Lacerda L, Somers S, Opie LH, Lecour S (2009) Ischaemic postconditioning protects against reperfusion injury via the SAFE pathway. Cardiovasc Res 84:201–208. https://doi.org/10.1093/cvr/cvp274 CrossRefPubMed

33.

Lamont KT, Somers S, Lacerda L, Opie LH, Lecour S (2011) Is red wine a SAFE sip away from cardioprotection? Mechanisms involved in resveratrol- and melatonin-induced cardioprotection. J Pineal Res 50:374–380. https://doi.org/10.1111/j.1600-079X.2010.00853.x CrossRefPubMed

34.

Lecour S (2009) Activation of the protective survivor activating factor enhancement (SAFE) pathway against reperfusion injury: does it go beyond the RISK pathway? J Mol Cell Cardiol 47:32–40. https://doi.org/10.1016/j.yjmcc.2009.03.019 CrossRefPubMed

35.

Lecour S, James RW (2011) When are pro-inflammatory cytokines SAFE in heart failure? Eur Heart J 32:680–685. https://doi.org/10.1093/eurheartj/ehq484 CrossRefPubMed

36.

Lecour S, Minners J, Rochette L, Opie LH, Sack MN (1999) Tumor necrosis factor alpha confers cardiac preconditioning—possible role of mitochondrial KATP channel mediated event. Circulation 100:S768. https://doi.org/10.1161/01.CIR.100.18.s768 CrossRef

37.

Lecour S, Rochette L, Opie L (2005) Free radicals trigger TNF alpha-induced cardioprotection. Cardiovasc Res 65:239–243. https://doi.org/10.1016/j.cardiores.2004.10.003 CrossRefPubMed

38.

Lecour S, Smith RM, Woodward B, Opie LH, Rochette L, Sack MN (2002) Identification of a novel role for sphingolipid signaling in TNF alpha and ischemic preconditioning mediated cardioprotection. J Mol Cell Cardiol 34:509–518. https://doi.org/10.1006/jmcc.2002.1533 CrossRefPubMed

39.

Lecour S, Suleman N, Deuchar GA, Somers S, Lacerda L, Huisamen B, Opie LH (2005) Pharmacological preconditioning with tumor necrosis factor-alpha activates signal transducer and activator of transcription-3 at reperfusion without involving classic prosurvival kinases (Akt and extracellular signal-regulated kinase). Circulation 112:3911–3918. https://doi.org/10.1161/CIRCULATIONAHA.105.581058 CrossRefPubMed

40.

Meier JA, Hyun M, Cantwell M, Raza A, Mertens C, Raje V, Sisler J, Tracy E, Torres-Odio S, Gispert S, Shaw PE, Baumann H, Bandyopadhyay D, Takabe K, Larner AC (2017) Stress-induced dynamic regulation of mitochondrial STAT3 and its association with cyclophilin D reduce mitochondrial ROS production. Sci Signal. https://doi.org/10.1126/scisignal.aag2588 PubMedPubMedCentral

41.

Muller J, Gorressen S, Grandoch M, Feldmann K, Kretschmer I, Lehr S, Ding Z, Schmitt JP, Schrader J, Garbers C, Heusch G, Kelm M, Scheller J, Fischer JW (2014) Interleukin-6-dependent phenotypic modulation of cardiac fibroblasts after acute myocardial infarction. Basic Res Cardiol 109:440. https://doi.org/10.1007/s00395-014-0440-y CrossRefPubMed

42.

Murry CE, Jennings RB, Reimer KA (1986) Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 74:1124–1136. https://doi.org/10.1161/01.CIR.74.5.1124 CrossRefPubMed

43.

Nan J, Hu H, Sun Y, Zhu L, Wang Y, Zhong Z, Zhao J, Zhang N, Wang Y, Wang Y, Ye J, Zhang L, Hu X, Zhu W, Wang J (2017) TNFR2 stimulation promotes mitochondrial fusion via Stat3- and NF-kB-dependent activation of OPA1 expression. Circ Res 121:392–410. https://doi.org/10.1161/CIRCRESAHA.117.311143 CrossRefPubMedPubMedCentral

44.

Nduhirabandi F, Lamont K, Albertyn Z, Opie LH, Lecour S (2016) Role of toll-like receptor 4 in melatonin-induced cardioprotection. J Pineal Res 60:39–47. https://doi.org/10.1111/jpi.12286 CrossRefPubMed

45.

O’Sullivan KE, Breen EP, Gallagher HC, Buggy DJ, Hurley JP (2016) Understanding STAT3 signaling in cardiac ischemia. Basic Res Cardiol 111:27. https://doi.org/10.1007/s00395-016-0543-8 CrossRefPubMed

46.

Pedretti S, Frias M, James R, Lecour S (2014) The cardioprotective effect of exogenous sphingosine-1-phosphate requires the activation of endogenous sphingosine-1-phosphate via the sphingosine kinase 1. Cardiovasc Res 103:S119. https://doi.org/10.1093/cvr/cvu098 CrossRef

47.

Penna C, Perrelli MG, Tullio F, Angotti C, Camporeale A, Poli V, Pagliaro P (2013) Diazoxide postconditioning induces mitochondrial protein S-nitrosylation and a redox-sensitive mitochondrial phosphorylation/translocation of RISK elements: no role for SAFE. Basic Res Cardiol 108:371. https://doi.org/10.1007/s00395-013-0371-z CrossRefPubMed

48.

Penna C, Settanni F, Tullio F, Trovato L, Pagliaro P, Alloatti G, Ghigo E, Granata R (2013) GH-releasing hormone induces cardioprotection in isolated male rat heart via activation of RISK and SAFE pathways. Endocrinology 154:1624–1635. https://doi.org/10.1210/en.2012-2064 CrossRefPubMed

49.

Sarzi-Puttini P, Atzeni F, Shoenfeld Y, Ferraccioli G (2005) TNF-alpha, rheumatoid arthritis, and heart failure: a rheumatological dilemma. Autoimmun Rev 4:153–161. https://doi.org/10.1016/j.autrev.2004.09.004 CrossRefPubMed

50.

Schulman D, Latchman DS, Yellon DM (2002) Urocortin protects the heart from reperfusion injury via upregulation of p42/p44 MAPK signaling pathway. Am J Physiol Heart Circ Physiol 283:H1481–H1488. https://doi.org/10.1152/ajpheart.01089.2001 CrossRefPubMed

51.

Schulz R, Heusch G (2009) Tumor necrosis factor-alpha and its receptors 1 and 2: Yin and Yang in myocardial infarction? Circulation 119:1355–1357. https://doi.org/10.1161/CIRCULATIONAHA.108.846105 CrossRefPubMed

52.

Skyschally A, Gent S, Amanakis G, Schulte C, Kleinbongard P, Heusch G (2015) Across-species transfer of protection by remote ischemic preconditioning with species-specific myocardial signal transduction by reperfusion injury salvage kinase and survival activating factor enhancement pathways. Circ Res 117:279–288. https://doi.org/10.1161/CIRCRESAHA.117.306878 CrossRefPubMed

53.

Smith RM, Lecour S, Sack MN (2002) Innate immunity and cardiac preconditioning: a putative intrinsic cardioprotective program. Cardiovasc Res 55:474–482. https://doi.org/10.1016/S0008-6363(02)00288-2 CrossRefPubMed

54.

Somers SJ, Frias M, Lacerda L, Opie LH, Lecour S (2012) Interplay between SAFE and RISK pathways in sphingosine-1-phosphate-induced cardioprotection. Cardiovasc Drugs Ther 26:227–237. https://doi.org/10.1007/s10557-012-6376-2 CrossRefPubMed

55.

Suleman N, Somers S, Smith R, Opie LH, Lecour SC (2008) Dual activation of STAT-3 and Akt is required during the trigger phase of ischaemic preconditioning. Cardiovasc Res 79:127–133. https://doi.org/10.1093/cvr/cvn067 CrossRefPubMed

56.

Szczepanek K, Chen Q, Derecka M, Salloum FN, Zhang Q, Szelag M, Cichy J, Kukreja RC, Dulak J, Lesnefsky EJ, Larner AC (2011) Mitochondrial-targeted Signal transducer and activator of transcription 3 (STAT3) protects against ischemia-induced changes in the electron transport chain and the generation of reactive oxygen species. J Biol Chem 286:29610–29620. https://doi.org/10.1074/jbc.M111.226209 CrossRefPubMedPubMedCentral

57.

Szczepanek K, Xu A, Hu Y, Thompson J, He J, Larner AC, Salloum FN, Chen Q, Lesnefsky EJ (2015) Cardioprotective function of mitochondrial-targeted and transcriptionally inactive STAT3 against ischemia and reperfusion injury. Basic Res Cardiol 110:53. https://doi.org/10.1007/s00395-015-0509-2 CrossRefPubMed

58.

Tanno M, Gorog DA, Bellahcene M, Cao X, Quinlan RA, Marber MS (2003) Tumor necrosis factor-induced protection of the murine heart is independent of p38-MAPK activation. J Mol Cell Cardiol 35:1523–1527. https://doi.org/10.1016/j.yjmcc.2003.09.019 CrossRefPubMed

59.

Watson AJ, Gao L, Sun L, Tsun J, Jabbour A, Ru Qiu M, Jansz PC, Hicks M, Macdonald PS (2013) Enhanced preservation of the rat heart after prolonged hypothermic ischemia with erythropoietin-supplemented Celsior solution. J Heart Lung Transplant 32:633–640. https://doi.org/10.1016/j.healun.2013.03.014 CrossRefPubMed

60.

Wegrzyn J, Potla R, Chwae YJ, Sepuri NB, Zhang Q, Koeck T, Derecka M, Szczepanek K, Szelag M, Gornicka A, Moh A, Moghaddas S, Chen Q, Bobbili S, Cichy J, Dulak J, Baker DP, Wolfman A, Stuehr D, Hassan MO, Fu XY, Avadhani N, Drake JI, Fawcett P, Lesnefsky EJ, Larner AC (2009) Function of mitochondrial Stat3 in cellular respiration. Science 323:793–797. https://doi.org/10.1126/science.1164551 CrossRefPubMedPubMedCentral

61.

Wu Q, Wang T, Chen S, Zhou Q, Li H, Hu N, Feng Y, Dong N, Yao S, Xia Z (2017) Cardiac protective effects of remote ischaemic preconditioning in children undergoing tetralogy of fallot repair surgery: a randomized controlled trial. Eur Heart J. https://doi.org/10.1093/eurheartj/ehx030

62.

Yu L, Li B, Zhang M, Jin Z, Duan W, Zhao G, Yang Y, Liu Z, Chen W, Wang S, Yang J, Yi D, Liu J, Yu S (2016) Melatonin reduces PERK–eIF2alpha–ATF4-mediated endoplasmic reticulum stress during myocardial ischemia–reperfusion injury: role of RISK and SAFE pathways interaction. Apoptosis 21:809–824. https://doi.org/10.1007/s10495-016-1246-1 CrossRefPubMed

63.

Zhao Y, Zheng ZN, Pi YN, Liang X, Jin SQ (2017) Cardioprotective effects of transfusion of late-phase preconditioned plasma may be induced by activating the reperfusion injury salvage kinase pathway but not the survivor activating factor enhancement pathway in rats. Oxid Med Cell Longev 2017:8526561. https://doi.org/10.1155/2017/8526561 PubMedPubMedCentral

Title: The SAFE pathway for cardioprotection: is this a promising target?
Authors: Nkanyiso Hadebe
Martin Cour
Sandrine Lecour
Publication date: 01-03-2018
Publisher: Springer Berlin Heidelberg
Published in: Basic Research in Cardiology / Issue 2/2018
Print ISSN: 0300-8428
Electronic ISSN: 1435-1803
DOI: https://doi.org/10.1007/s00395-018-0670-5

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

The SAFE pathway for cardioprotection: is this a promising target?

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2018

Phosphorylation of vasodilator-stimulated phosphoprotein contributes to myocardial ischemic preconditioning

Amphiregulin enhances cardiac fibrosis and aggravates cardiac dysfunction in mice with experimental myocardial infarction partly through activating EGFR-dependent pathway

Cardioprotective effect of ghrelin against myocardial infarction-induced left ventricular injury via inhibition of SOCS3 and activation of JAK2/STAT3 signaling

Molecular imaging of cardiac remodelling after myocardial infarction

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page